Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of CosmeRNA-ARI Anti Hair Loss Tonic in Adults With Androgenetic Alopecia
Sponsor: BIONEER Corporation
Summary
This study evaluated the efficacy and safety of two concentrations of CosmeRNA-ARI Anti Hair Loss Tonic in adults with androgenetic alopecia. Participants were randomly assigned to receive the low-concentration investigational product, the high-concentration investigational product, or a vehicle control product without the active ingredient. Each assigned product was applied to the scalp once every 2 weeks for 24 weeks. Hair density, hair thickness, hair growth rate, expert-assessed changes in hair density, participant-reported outcomes, and scalp safety were evaluated. The study was designed to determine whether the investigational products improved hair growth-related outcomes compared with the vehicle control product.
Official title: A 24-Week, Double-Blind, Placebo-Controlled, Randomized Human Application Study to Evaluate the Efficacy and Safety of CosmeRNA-ARI Anti Hair Loss Tonic in Adults With Androgenetic Alopecia
Key Details
Gender
All
Age Range
18 Years - 54 Years
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2024-12-16
Completion Date
2026-01-22
Last Updated
2026-10-27
Healthy Volunteers
No
Conditions
Interventions
Low-Concentration CosmeRNA-ARI Anti Hair Loss Tonic
A transparent liquid cosmetic scalp formulation containing CosmeRNA-AR at the lower concentration evaluated in this study. The product was applied topically to the scalp by study personnel once every 2 weeks for 24 weeks, for a total of 12 applications.
High-Concentration CosmeRNA-ARI Anti Hair Loss Tonic
A transparent liquid cosmetic scalp formulation containing CosmeRNA-AR at the higher concentration evaluated in this study. The product was applied topically to the scalp by study personnel once every 2 weeks for 24 weeks, for a total of 12 applications.
Vehicle Control Tonic Without CosmeRNA-AR
A transparent liquid cosmetic scalp formulation without CosmeRNA-AR. The control product was applied using the same method and schedule as the investigational products: once every 2 weeks for 24 weeks, for a total of 12 applications.
Locations (1)
P&K Skin Research Center Co., Ltd.
Seoul, South Korea